Navigation Links
ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
Date:11/25/2009

MOUNTAIN VIEW, Calif., Nov. 25 /PRNewswire/ -- ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The study demonstrated evidence of clinical efficacy in the reduction of disease severity as defined as a 70-point decrease in the Crohn's Disease Activity Index (CDAI) in patients treated with Traficet-EN over the course of 12 weeks; the more stringent measure of at least a 100-point decrease in the CDAI score was also met by week 12. In addition, Traficet-EN treatment benefited patients who had previously not responded to anti-TNF treatment. These results reported from the Induction phase of the PROTECT-1 trial, were presented today in a poster titled "PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B (TRAFICET-EN) in Crohn's Disease" by Satish Keshav, M.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University at the GASTRO 2009 United European Gastroenterology Federation and World Gastroenterology Organization (UEGW/WCOG) conference in London.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

Study Results

Results showed that the CDAI >/= 70-point response in patients with small bowel and/or colonic Crohn's disease treated with 500 mg once-daily dose (QD) of Traficet-EN for 12 weeks was
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
(Date:12/15/2014)... YORK and HERZLIYA PITUACH, Israel ... "Company") (NASDAQ: IMNP ) announced today that its ... the Board succeeding Dr. Daniel Teper who continues ... a member of Immune,s Board of Directors since 2013. ... "I am delighted to represent the interest of shareholders and ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... LAKE, N.J., Jan. 3, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ... has submitted its response to the Complete Response Letter (CRL) ... review of the lorcaserin New Drug Application (NDA). Lorcaserin is ... weight loss, in patients who are obese (Body Mass Index, ...
... Jan. 3, 2012 IDEXX Laboratories, Inc. (NASDAQ: ... 30 th Annual J.P. Morgan Healthcare Conference. Jonathan W. ... on the Company on Monday, January 9, 2012 at 2:30 ... California. Individuals can access the live audio webcast of the ...
Cached Medicine Technology:Arena Submits Response to FDA Complete Response Letter for Lorcaserin 2Arena Submits Response to FDA Complete Response Letter for Lorcaserin 3Arena Submits Response to FDA Complete Response Letter for Lorcaserin 4Arena Submits Response to FDA Complete Response Letter for Lorcaserin 5Arena Submits Response to FDA Complete Response Letter for Lorcaserin 6
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Deerfield Valley, announced today that it has unveiled its ... , Three time Grammy Award Winner Kenny Loggins ... by a trail naming ceremony. Hermitage Club Founder, President ... Alright” the theme song for the movie soundtrack to ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... at least 20 seconds you may be at risk of ... leg may indicate that small strokes or tiny bleeds have ... is high, the investigators reported online Dec. 18 in the ... on one leg, as well as problems walking, should receive ...
(Date:12/17/2014)... 17, 2014 This prestigious award ... that have made outstanding and innovative contributions to ... progression of private practice physical therapy by the ... Association. , On behalf of Performance Physical Therapy, ... CEO of Performance accepted the award at the ...
(Date:12/17/2014)... No matter how far modern medicine advances, it ... louse parasite—a common childhood malady and a source of ... and twelve million individuals will suffer an infestation. ... comes to the rescue, providing an all-natural treatment that ... record of customer service, and effectiveness in getting rid ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... A multi-institutional team of engineers, scientists and clinicians ... biomechanics that could play a role in heart ... ,Patients who have the disease may ... tissue accumulates, blood flow is blocked and tiny ...
... researchers are developing a bioactive paper that can detect ... and viruses, like E-coli, salmonella and SARS. ... active chemicals and can be used in manufacturing products ... salmonella in food, and hospital masks for detecting and ...
... guidelines say daily consumption of fish oil supplements could prevent ... ,New guidelines by the National Institute for Health and ... fatty acids every day to reduce the risk of having ... ,Omega 3 fatty acids are important throughout adult life ...
... and psychological treatments such as hypnotherapy have the potential ... (IBS), say researchers in this weeks BMJ. ... treatments often do not work very well and patients ... or misunderstood. ,Patients with IBS are more ...
... over the past 40 years in England, owing to changes ... finds research published ahead of print in the British Journal ... geographical variation in rates suggest that the NHS is now ... training, say the authors. ,The research team analysed ...
... first human case of avian influenza since 2005, state media ... has officially confirmed that a 29-year-old man has been infected ... case was reported, according to Vietnam News Agency. ... capital Hanoi, began suffering from high fever and breathing difficulties ...
Cached Medicine News:Health News:Research may Yield Improved Treatment for Diseased Lungs 2Health News:Study on Bioactive Paper That can Detect Life Threatening Bacteria and Viruses 2Health News:Hypnotherapy may Help Patients With Irritable Bowel Syndrome 2Health News:NHS Oversupplied With Cataract Surgery, Say Doctors 2
Porous foundation 470 series....
The Opteon stem meets the challenge of providing a high-quality, cost-effective hip implant for the moderate demand patient....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The link ribbed hip stem for cementless primary hip replacement surgery....
Medicine Products: